Systemically delivered, tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases.
We are creating molecules that are systemically delivered, tissue-directed and locally active. We are advancing a pipeline of therapies that enable new approaches for patients with cancer, chronic viral infections and other serious diseases.
Our lead product candidate, SBT6050, is comprised of a TLR8 linker-payload conjugated to a HER2-directed monoclonal antibody, designed to activate myeloid cells in tumors expressing moderate or high levels of HER2. TLR8 is expressed in myeloid cell subpopulations prevalent in human tumors, and TLR8 agonism can activate a broad spectrum of anti-tumor immune mechanisms.
We are currently evaluating the safety and tolerability of SBT6050 in a Phase 1/1b clinical trial in patients with advanced or metastatic HER2-expressing solid tumors. We are actively recruiting for this study, and we anticipate providing an update on interim data from the Phase 1 monotherapy dose-escalation cohorts in the second half of 2021.
SBT6290 is comprised of a TLR8 linker-payload conjugated to a monoclonal antibody targeting Nectin4. Nectin4 is expressed in subsets of solid tumors including bladder, triple negative breast, head and neck, and non-small cell lung cancers. We expect to file an IND for this program in the fourth quarter of 2021.
SBT8230, an ASGR1-TLR8 ImmunoTAC therapeutic, is our third TLR8 program. SBT8230 is engineered to potently activate human myeloid cells in the liver for the treatment of chronic hepatitis (cHBV). We believe liver-localized TLR8 agonism can best realize the potential for effective therapy and potentially lead to functional cures in patients suffering from cHBV. We selected a development candidate for this program in the fourth quarter of 2020.
Additional
In addition to SBT6050 and SBT6290, we are evaluating other solid tumor targets to leverage the TLR8 linker-payload paired with additional tumor-directed antibodies. These targets are differentially expressed on tumors compared to normal tissue.
TGFβR Antagonist Conjugates
TGFβ signaling is a key mediator of fibrosis across multiple organ systems, including the liver. Our ASGR1-TGFβR1 antagonist conjugate pairs the ASGR1 antibody used in SBT8230 with a proprietary TGFβR1 antagonist to achieve liver-localized inhibition of TGFβ signaling to treat fibrosis. Our tissue-directed approach has been designed to prevent toxicities associated with untargeted systemically distributed TGFβR1 antagonist agents.
